Diabetes
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Diabetes patients aged 18–70 years, treated for their diabetes by the recruiting health care provider, sufficiently fluent in Chinese, wtih the ability to use smartphones and proficient in using smartphone applications.The patient has the ability of daily blood glucose measurement, and the patient can sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) with presence of cognitive impairment or psychiatric disorders; (2) when diagnosed with type 1 diabetes mellitus, gestational diabetes mellitus or special types of diabetes mellitus. (3) with severe heart, liver or kidney failure, malignant tumors or other serious diseases; (4) when refused to sign the informed consent; (5) with pregnancy during the planned study; (6) with a history of alcoholism and drug abuse; (7) when using drugs that may affect blood glucose levels, such as glucocorticoids and thyroid hormones; (8) with cardiovascular and cerebrovascular events occurred within 6 months before enrollment; (9) with severe hearing or visual impairment; (10) when unable to access the network or learn to use smart phones; (11) or if patients are simultaneously participating in another clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin A1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight;Fasting blood glucose;2-Hour postprandial blood glucose ;Triglyceride;Cholesterol;Low density lipoprotein cholesterol;High density lipoprotein cholesterol;Creatinine;Urea;Uric acid;Urinary microalbumin / creatinine;Presence of microvascular complications ;Presence of macrovascular complications;The Short Form (36) Health Survey;The Audit of Diabetes-Dependent Quality of Life (ADDQoL);Diabetes Treatment Satisfaction Questionnaire (DTSQ);Summary of Diabetes Self-Care Activities Measure (SDSCA);Body mass index;Blood pressure;Waist circumference;Hip perimeter;Insulin;C-peptide;Homeostasis model assessment of insulin resistance ( HOMA-IR);Homeostasis model assessment of ß cell function (HOMA-ß;The perceived quality of APP;The frequency of application usage;the cost-effectiveness ;Glutamic-pyruvic transaminase ;Glutamic oxaloacetic transaminase ;EuroQol 5 Dimensions 5 Level instrument (EQ-5D-5L); | — |
Countries
China
Contacts
Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing Jiangning Hospital